company background image
VXLL.F logo

Vaxil Bio OTCPK:VXLL.F Stock Report

Last Price

US$0.008

Market Cap

US$1.0m

7D

0%

1Y

-60.0%

Updated

20 Aug, 2024

Data

Company Financials

VXLL.F Stock Overview

A biotechnology company, focuses on a novel drug discovery and development platform based on signal peptides for infectious diseases and cancer. More details

VXLL.F fundamental analysis
Snowflake Score
Valuation1/6
Future Growth0/6
Past Performance0/6
Financial Health6/6
Dividends0/6

My Notes

Capture your thoughts, links and company narrative

Vaxil Bio Ltd. Competitors

Price History & Performance

Summary of share price highs, lows and changes for Vaxil Bio
Historical stock prices
Current Share PriceCA$0.008
52 Week HighCA$0.06
52 Week LowCA$0.0021
Beta0
1 Month Change0%
3 Month Change33.33%
1 Year Change-60.00%
3 Year Change-86.89%
5 Year Change-75.02%
Change since IPO-95.56%

Recent News & Updates

Recent updates

Shareholder Returns

VXLL.FUS BiotechsUS Market
7D0%-3.8%-2.7%
1Y-60.0%-2.6%23.4%

Return vs Industry: VXLL.F underperformed the US Biotechs industry which returned 15.7% over the past year.

Return vs Market: VXLL.F underperformed the US Market which returned 25.6% over the past year.

Price Volatility

Is VXLL.F's price volatile compared to industry and market?
VXLL.F volatility
VXLL.F Average Weekly Movementn/a
Biotechs Industry Average Movement10.7%
Market Average Movement6.3%
10% most volatile stocks in US Market16.9%
10% least volatile stocks in US Market3.2%

Stable Share Price: VXLL.F's share price has been volatile over the past 3 months.

Volatility Over Time: Insufficient data to determine VXLL.F's volatility change over the past year.

About the Company

FoundedEmployeesCEOWebsite
2006n/aDavid Gorenvaxil-bio.com

Vaxil Bio Ltd., a biotechnology company, focuses on a novel drug discovery and development platform based on signal peptides for infectious diseases and cancer. The company develops ImMucin, a MUC1 SP-derived vaccine that has completed a Phase 1/2 clinical trial for the treatment of multiple myeloma. It is also developing SP-based COVID-19 and tuberculosis vaccine/treatment candidate.

Vaxil Bio Ltd. Fundamentals Summary

How do Vaxil Bio's earnings and revenue compare to its market cap?
VXLL.F fundamental statistics
Market capUS$1.00m
Earnings (TTM)-US$137.13k
Revenue (TTM)n/a

0.0x

P/S Ratio

-7.3x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
VXLL.F income statement (TTM)
RevenueCA$0
Cost of RevenueCA$0
Gross ProfitCA$0
Other ExpensesCA$187.00k
Earnings-CA$187.00k

Last Reported Earnings

Mar 31, 2024

Next Earnings Date

n/a

Earnings per share (EPS)-0.0014
Gross Margin0.00%
Net Profit Margin0.00%
Debt/Equity Ratio0%

How did VXLL.F perform over the long term?

See historical performance and comparison

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/08/20 15:34
End of Day Share Price 2024/05/23 00:00
Earnings2024/03/31
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Vaxil Bio Ltd. is covered by 0 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution